Neuroscience

Psychiatric disorders are highly prevalent, impacting 1 in every 8 people worldwide, and are a leading cause of disease burden. They are characterized by a wide range of symptoms that can affect mood, thought processes, behavior and overall mental functioning. Over the last 30 years, our scientists and clinicians have worked to tackle the complexity of psychiatric disorders, and today we offer a portfolio of medicines and a pipeline targeting conditions such as depression, anxiety, bipolar disorder and schizophrenia.

Migraine is more than a headache – it’s a neurological disease that causes pain and debilitating symptoms, affecting 1 billion people worldwide. Building on our established leadership in migraine through treatments designed to meet patient needs across the full spectrum of the disease, we are relentlessly pursuing innovative approaches that may transform the future of migraine treatment. These include evaluating both acute and preventive therapies that target the underlying mechanisms of migraine and advancing next-generation therapies that may help non-responders and address non-headache symptoms.

From Parkinson’s disease to specific types of spasticity, essential tremor and more, our commitment to people living with movement disorders is unwavering. These chronic and progressive conditions affect the body’s ability to control movement. Recognizing the profound impact these conditions have on quality of life, our dedicated teams are focused on understanding the root causes of these disorders to develop treatments that can help mitigate symptoms and potentially modify or slow the progression of disease.

Neurodegenerative disorders are a group of diseases characterized by the progressive degeneration of the structure and function of the nervous system. These conditions often lead to a decline in cognitive and physical abilities, affecting memory, movement and overall brain function over time. Over 50 million people worldwide are affected by neurodegenerative diseases, a number expected to rise as the population ages. By leveraging our deep expertise in disease biology and cutting-edge technologies and platforms, we are advancing research to develop treatments aimed at ameliorating symptoms or slowing down the progression of disease for conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and vanishing white matter disease.